Cargando…

Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases

At the end of 2019, respiratory coronavirus diseases 2019 (COVID‐19) appeared and spread rapidly in the world. Besides several mutations, the outcome of this pandemic was the death up to 15% of hospitalized patients. Mesenchymal stromal cell therapy as a therapeutic strategy seemed successful in tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Banimohamad‐Shotorbani, Behnaz, Farajpour, Hekmat, Sefat, Farshid, Khosroshahi, Shiva Ahdi, Shafaei, Hajar, Heidari keshel, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014656/
https://www.ncbi.nlm.nih.gov/pubmed/33629351
http://dx.doi.org/10.1002/bit.27729
_version_ 1783673569146830848
author Banimohamad‐Shotorbani, Behnaz
Farajpour, Hekmat
Sefat, Farshid
Khosroshahi, Shiva Ahdi
Shafaei, Hajar
Heidari keshel, Saeed
author_facet Banimohamad‐Shotorbani, Behnaz
Farajpour, Hekmat
Sefat, Farshid
Khosroshahi, Shiva Ahdi
Shafaei, Hajar
Heidari keshel, Saeed
author_sort Banimohamad‐Shotorbani, Behnaz
collection PubMed
description At the end of 2019, respiratory coronavirus diseases 2019 (COVID‐19) appeared and spread rapidly in the world. Besides several mutations, the outcome of this pandemic was the death up to 15% of hospitalized patients. Mesenchymal stromal cell therapy as a therapeutic strategy seemed successful in treatment of several diseases. Not only mesenchymal stromal cells of several tissues, but also their secreted extracellular vesicles and even secretome indicated beneficial therapeutic function. All of these three options were studied for treatment of COVID‐19 as well as those respiratory diseases that have similar symptom. Fortunately, most of the outcomes were promising and optimistic. In this paper, we review in‐vivo and clinical studies which have been used different sources of mesenchymal stromal cell, secreted extracellular vesicles, and secretome to improve and treat symptoms of COVID‐19 and similar lung diseases.
format Online
Article
Text
id pubmed-8014656
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80146562021-04-01 Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases Banimohamad‐Shotorbani, Behnaz Farajpour, Hekmat Sefat, Farshid Khosroshahi, Shiva Ahdi Shafaei, Hajar Heidari keshel, Saeed Biotechnol Bioeng REVIEWS At the end of 2019, respiratory coronavirus diseases 2019 (COVID‐19) appeared and spread rapidly in the world. Besides several mutations, the outcome of this pandemic was the death up to 15% of hospitalized patients. Mesenchymal stromal cell therapy as a therapeutic strategy seemed successful in treatment of several diseases. Not only mesenchymal stromal cells of several tissues, but also their secreted extracellular vesicles and even secretome indicated beneficial therapeutic function. All of these three options were studied for treatment of COVID‐19 as well as those respiratory diseases that have similar symptom. Fortunately, most of the outcomes were promising and optimistic. In this paper, we review in‐vivo and clinical studies which have been used different sources of mesenchymal stromal cell, secreted extracellular vesicles, and secretome to improve and treat symptoms of COVID‐19 and similar lung diseases. John Wiley and Sons Inc. 2021-03-27 2021-06 /pmc/articles/PMC8014656/ /pubmed/33629351 http://dx.doi.org/10.1002/bit.27729 Text en © 2021 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals LLC https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle REVIEWS
Banimohamad‐Shotorbani, Behnaz
Farajpour, Hekmat
Sefat, Farshid
Khosroshahi, Shiva Ahdi
Shafaei, Hajar
Heidari keshel, Saeed
Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases
title Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases
title_full Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases
title_fullStr Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases
title_full_unstemmed Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases
title_short Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases
title_sort efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for covid‐19 and similar lung diseases
topic REVIEWS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014656/
https://www.ncbi.nlm.nih.gov/pubmed/33629351
http://dx.doi.org/10.1002/bit.27729
work_keys_str_mv AT banimohamadshotorbanibehnaz efficacyofmesenchymalstromalcellsandcellularproductsinimprovementofsymptomsforcovid19andsimilarlungdiseases
AT farajpourhekmat efficacyofmesenchymalstromalcellsandcellularproductsinimprovementofsymptomsforcovid19andsimilarlungdiseases
AT sefatfarshid efficacyofmesenchymalstromalcellsandcellularproductsinimprovementofsymptomsforcovid19andsimilarlungdiseases
AT khosroshahishivaahdi efficacyofmesenchymalstromalcellsandcellularproductsinimprovementofsymptomsforcovid19andsimilarlungdiseases
AT shafaeihajar efficacyofmesenchymalstromalcellsandcellularproductsinimprovementofsymptomsforcovid19andsimilarlungdiseases
AT heidarikeshelsaeed efficacyofmesenchymalstromalcellsandcellularproductsinimprovementofsymptomsforcovid19andsimilarlungdiseases